Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension

doi:10.1056/NEJMct0904473

Volume 361:1864-1871		November 5, 2009		Number 19

Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial Hypertension

Stephen L. Archer, M.D., and Evangelos D. Michelakis, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

Full Text

PDF

PDA Full Text

PowerPoint Slide Set

CME Exam

Supplementary Material

Purchase this article

Add to Personal Archive

Add to Citation Manager

Notify a Friend

E-mail When Cited

E-mail When Letters Appear

PubMed Citation

This Journal feature begins with a case vignette that includesa therapeutic recommendation. A discussion of the clinical problemand the mechanism of benefit of this form of therapy follows.Major clinical studies, the clinical use of this therapy, andpotential adverse effects are reviewed. Relevant formal guidelines,if they exist, are presented. The article ends with the authors'clinical recommendations.

A 46-year-old woman presents with progressive exertional dyspneaand recurrent exertional syncope. Her jugular venous pressureis 16 cm of water, and moderate peripheral edema is noted. Auscultationreveals a pronounced pulmonic component of the second heartsound and . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Section of Cardiology, Department of Medicine, University of Chicago, Chicago (S.L.A.); and the Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, AB, Canada (E.D.M.).

Address reprint requests to Dr. Archer at the University of Chicago, 5841 S. Maryland Ave. (MC6080), Chicago, IL 60637, or at sarcher@medicine.bsd.uchicago.edu.